18 Jan Arbor Biotechnologies
Posted at 18:36h
in
Devyn Smith, Ph.D., CEO
April 15 | 2:00pm | Salone dei Cavalieri, Section 2
Cambridge, MA
(Private)
At Arbor, we are discovering, developing and making available to all patients the next generation of genetic medicines. We are disrupting the field through our proprietary discovery engine to develop a portfolio of differentiated genetic editing and delivery capabilities. We have an unencumbered portfolio of multiple CRISPR based genetic modifiers that can be tailored to correct the underlying pathology of each genetic disease. Our pipeline of genetic medicines will focus on bringing cures to all patients with genetic disease.
